Cosentyx Gains FDA Approval for Scalp Psoriasis

The FDA has approved a label update for secukinumab (Cosentyx) for the treatment of moderate-to-severe scalp psoriasis, according to a Novartis press release. Scalp psoriasis affects approximately half of patients with psoriasis and is notoriously difficult to treat due to the presence of hair and other related factors.

The label will be updated in the United States immediately, according to the release.

“Scalp psoriasis is on a very sensitive, and a very visible area of the body. For patients this could translate into physical pain, frustration and social isolation,” said Kristian Reich, MD, PhD, Georg-August-University Göttingen and Dermatologikum Hamburg, Germany. “Patients and doctors are in need of effective treatment options in this and other difficult-to-treat forms of psoriasis."

Source: Cosentyx Gains FDA Approval for Scalp Psoriasis

thumbnail courtesy of specialtypharmacytimes.com

Check out other psoriasis news here.

Additional reading: The Top 3 Psoriasis Shampoos – The Best Over the Counter Psoriasis Shampoo

Cosentyx Gains FDA Approval for Scalp Psoriasis was originally published to: Psoriasis Zap Blog

Comments

Popular posts from this blog

Gold Bond Psoriasis Relief Cream Review

MG217 Psoriasis Cream Review

How Does MetaDerm Psoriasis Cream Compare to Competitors?